BAIYUNSHAN PH (00874) Subsidiary Receives Drug Supplementary Application Approval Certificates

Stock News

09/16

BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Medical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory (referred to as "Baiyunshan Pharmaceutical General Factory"), has recently received "Drug Supplementary Application Approval Notifications" issued by the National Medical Products Administration.

According to the announcement, Baiyunshan Pharmaceutical General Factory obtained Drug Supplementary Application Approval Notifications for Fukean tablets, Kunling pills, Shenxi Dan, Yiganning tablets, and Maian granules. The approvals enhance safety and other information for these pharmaceutical products, contributing to their safe, effective, and rational use, while helping to improve the products' market competitiveness.

The company noted that receiving these Drug Supplementary Application Approval Notifications will not have a significant impact on its current financial performance.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1106459077"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106459077\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106459077?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-16 17:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106459077","market":"fut","top_or_hot":-1,"title":"BAIYUNSHAN PH (00874) Subsidiary Receives Drug Supplementary Application Approval Certificates","media":"Stock News","content":"<p>BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Medical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory (referred to as \"Baiyunshan Pharmaceutical General Factory\"), has recently received \"Drug Supplementary Application Approval Notifications\" issued by the National Medical Products Administration.</p>\n<p>According to the announcement, Baiyunshan Pharmaceutical General Factory obtained Drug Supplementary Application Approval Notifications for Fukean tablets, Kunling pills, Shenxi Dan, Yiganning tablets, and Maian granules. The approvals enhance safety and other information for these pharmaceutical products, contributing to their safe, effective, and rational use, while helping to improve the products' market competitiveness.</p>\n<p>The company noted that receiving these Drug Supplementary Application Approval Notifications will not have a significant impact on its current financial performance.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAIYUNSHAN PH (00874) Subsidiary Receives Drug Supplementary Application Approval Certificates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAIYUNSHAN PH (00874) Subsidiary Receives Drug Supplementary Application Approval Certificates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-16 17:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Medical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory (referred to as \"Baiyunshan Pharmaceutical General Factory\"), has recently received \"Drug Supplementary Application Approval Notifications\" issued by the National Medical Products Administration.</p>\n<p>According to the announcement, Baiyunshan Pharmaceutical General Factory obtained Drug Supplementary Application Approval Notifications for Fukean tablets, Kunling pills, Shenxi Dan, Yiganning tablets, and Maian granules. The approvals enhance safety and other information for these pharmaceutical products, contributing to their safe, effective, and rational use, while helping to improve the products' market competitiveness.</p>\n<p>The company noted that receiving these Drug Supplementary Application Approval Notifications will not have a significant impact on its current financial performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0097","symbol_name":"医药电商","start_time":0,"source_url":"","article_id":"1106459077","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106459077","pubTimestamp":1758014063,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Medical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory (referred to as \"Baiyunshan Pharmaceutical General...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600332":"白云山","BK0097":"医药电商","BK0239":"医药制造","BK1197":"保健护理产品经销商","01477":"欧康维视生物-B","BK0096":"民营医院","BK1521":"挪威政府全球养老基金持仓","BK0183":"MSCI概念","00874":"白云山","BK0188":"融资融券","BK0012":"证金概念","BK0028":"国家队","BK1191":"制药","BK0175":"白马股","BK1606":"中医药概念","BK0070":"员工持股","BK1515":"抗疫概念","BK1574":"生物医药B类股","BK0196":"行业龙头"},"translate_title":"白云山PH(00874)子公司获药品补充申请批准证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":1,"00874":1,"01477":1},"content_text":"BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Medical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory (referred to as \"Baiyunshan Pharmaceutical General Factory\"), has recently received \"Drug Supplementary Application Approval Notifications\" issued by the National Medical Products Administration.\nAccording to the announcement, Baiyunshan Pharmaceutical General Factory obtained Drug Supplementary Application Approval Notifications for Fukean tablets, Kunling pills, Shenxi Dan, Yiganning tablets, and Maian granules. The approvals enhance safety and other information for these pharmaceutical products, contributing to their safe, effective, and rational use, while helping to improve the products' market competitiveness.\nThe company noted that receiving these Drug Supplementary Application Approval Notifications will not have a significant impact on its current financial performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}